Mundipharma buys Spanish biosimilars maker Cinfa Biotech

Home/Pharma News | Posted 12/10/2018 post-comment0 Post your comment

UK-based Mundipharma International (Mundipharma) is strengthening its position in biosimilars with the acquisition of Spanish biosimilars maker Cinfa Biotech.

Teamwork check mark V13D12

Mundipharma, which consists of a network of independent companies operating in over 120 countries worldwide, announced on 10 October 2018 that it had ‘added development capabilities to its biosimilars platform with the purchase of biosimilars development company Cinfa Biotech’.

Mundipharma acquires 100% ownership from parent company Infarco. The purchase gives the Mundipharma network (which includes NAPP Pharmaceuticals in the UK) immediate access to pegfilgrastim biosimilar Pelmeg (B12019). Pelmeg received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on 20 September 2018 [1]. The company estimates the potential global market for Pelmeg to be worth US$4.5 billion. In addition, Cinfa has one other undisclosed biosimilar in its pipeline.

Mundipharma already has an existing partnership with Celltrion for infliximab biosimilar Remsima (CT‑P13) [2] and rituximab biosimilar Truxima (CT‑P10). The company estimates that these biosimilars have saved healthcare systems approximately Euros 330 million.

Related article
Additional clinical data for Cinfa’s pegfilgrastim biosimilar

1.  GaBI Online - Generics and Biosimilars Initiative. EMA approves pegfilgrastim biosimilars Fulphila, Pelmeg and Ziextenzo []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Oct 12]. Available from:
2.  GaBI Online - Generics and Biosimilars Initiative. Infliximab biosimilar to be distributed by Mundipharma []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Oct 12]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Mundipharma

comment icon Comments (0)
Post your comment
Related content
Licensing agreements signed for ustekinumab biosimilars
Home/Pharma News Posted 17/09/2021
Oncogen–BrightGene partnership
104 MD001918
Home/Pharma News Posted 10/09/2021
Menagen–CKD Middle Eastern partnership
01 AA007239
Home/Pharma News Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010